银屑病外用药物治疗研究进展

中华皮肤科杂志 ›› 2016, Vol. 49 ›› Issue (4): 296-299.

银屑病外用药物治疗研究进展

郑晓枫,晋红中

中国医学科学院北京协和医学院北京协和医院皮肤科

收稿日期:2016-01-12 修回日期:2016-02-13 出版日期:2016-04-15 发布日期:2016-03-28
通讯作者: 晋红中 E-mail:jinhongzhong@263.net
基金资助:
北京市自然科学基金资助项目

Topical drugs for the treatment of psoriasis

Xiao-Feng ZHENG¹,

Received:2016-01-12 Revised:2016-02-13 Online:2016-04-15 Published:2016-03-28
Supported by:
Beijing Municipal Natural Science Foundation

摘要/Abstract

摘要：

近年来银屑病发病机制的研究有了较大的进展，为银屑病的治疗提供了多个新的靶点，将银屑病的治疗，尤其是局部治疗领入了新的时代。一些与传统银屑病外用药物的作用机制不同的新型靶向外用治疗药物已用于临床，主要为针对参与银屑病发病的细胞信号传导通路或酶如，JAK/STAT、PDE4、MEK、血管内皮生长因子受体、TrKA、RORγ等的小分子抑制剂。目前多项此类药物的Ⅰ期、Ⅱ期临床试验正在开展，部分已经完成的临床试验表明，这些药物对银屑病患者具有良好的有效性、安全性及耐受性，为银屑病患者的局部治疗提供了更多的选择。

Abstract:

Zheng Xiaofeng, Jin Hongzhong Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China Corresponding author: Jin Hongzhong, Email: jinhongzhong@263.net 【Abstract】 In recent years, great progress has been made in the pathogenesis of psoriasis, which has provided multiple new targets for the treatment of psoriasis, and ushered the treatment, especially topical treatment, of psoriasis to a new era. Some new targeted topical drugs with action mechanisms different from those of traditional drugs have been applied in clinical practice, which are mainly small-molecule inhibitors targeting cell signaling pathways or enzymes involved in the pathogenesis of psoriasis, such as the Janus kinase/signal transducer and activator of transcription （JAK/STAT） pathway, phosphodiesterase type 4 （PDE4）, mitogen-activated/extracellular-signal-regulated kinase kinase （MEK）, vascular endothelial growth factor receptor （VEGFR）, tropomyosin receptor kinase A （TrKA）, retinoic acid receptor-related orphan receptor γ （RORγ）, and so on. At present, many phaseⅠ and Ⅱ clinical trials are conducted for these drugs. Some completed trials have shown that they have good effectiveness, safety and tolerance, providing more options for the topical treatment of psoriasis.

郑晓枫晋红中. 银屑病外用药物治疗研究进展[J]. 中华皮肤科杂志, 2016, 49(4): 296-299.

Xiao-Feng ZHENG. Topical drugs for the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2016, 49(4): 296-299.

参考文献 20

［1］	Palanivel JA, Macbeth AE, Chetty NC, et al. An insight into JAK-STAT signalling in dermatology［J］. Clin Exp Dermatol, 2014, 39（4）: 513⁃518. DOI: 10.1111/ced.12273.
［2］	Ghoreschi K, Laurence A, O′Shea JJ. Janus kinases in immune cell signaling［J］. Immunol Rev, 2009, 228（1）: 273⁃287. DOI: 10.1111/j.1600⁃065X.2008.00754.x.
［3］	Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib （CP⁃690,550）［J］. J Immunol, 2011, 186（7）: 4234⁃4243. DOI: 10.4049/jimmunol.1003668.
［4］	Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial［J］. Lancet, 2015, 386（9993）: 552⁃561. DOI: 10.1016/S0140⁃6736（14）62113⁃9.
［5］	Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis［J］. Br J Dermatol, 2013, 169（1）: 137⁃145. DOI: 10.1111/bjd.12266.
［6］	Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis［J］. IDrugs, 2010, 13（6）: 394⁃403.
［7］	Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor［J］. Br J Dermatol, 2015, 173（4）: 989⁃997. DOI: 10.1111/bjd.13994.
［8］	Abroun S, Saki N, Ahmadvand M, et al. STATs: An old story, yet mesmerizing［J］. Cell J, 2015, 17（3）: 395⁃411.
［9］	Shi X, Jin L, Dang E, et al. IL⁃17A upregulates keratin 17 in keratinocytes through STAT1⁃ and STAT3⁃dependent mechanisms［J］. J Invest Dermatol, 2011, 131（12）: 2401⁃2408. DOI: 10.1038/jid.2011.222.
［10］	Andrés RM, Montesinos MC, Navalón P, et al. NF⁃κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH［J］. J Invest Dermatol, 2013, 133（10）: 2362⁃2371. DOI: 10.1038/jid.2013.182.
［11］	Kim BH, Lee JM, Jung YG, et al. Phytosphingosine derivatives ameliorate skin inflammation by inhibiting NF⁃κB and JAK/STAT signaling in keratinocytes and mice［J］. J Invest Dermatol, 2014, 134（4）: 1023⁃1032. DOI: 10.1038/jid.2013.453.
［12］	Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor［J］. J Invest Dermatol, 2011, 131（1）: 108⁃117. DOI: 10.1038/jid.2010.255.
［13］	Moustafa F, Feldman SR. A review of phosphodiesterase⁃inhibition and the potential role for phosphodiesterase 4⁃inhibitors in clinical dermatology［J］. Dermatol Online J, 2014, 20（5）: 22608.
［14］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phaseⅢ, randomized, controlled trial （efficacy and safety trial evaluating the effects of apremilast in psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015, 73（1）: 37⁃49. DOI: 10.1016/j.jaad.2015.03.049.
［15］	Akama T, Baker SJ, Zhang YK, et al. Discovery and structure⁃activity study of a novel benzoxaborole anti⁃inflammatory agent （AN2728） for the potential topical treatment of psoriasis and atopic dermatitis［J］. Bioorg Med Chem Lett, 2009, 19（8）: 2129⁃2132. DOI: 10.1016/j.bmcl.2009.03.007.
［16］	Muramoto K, Goto M, Inoue Y, et al. E6201, a novel kinase inhibitor of mitogen⁃activated protein kinase/extracellular signal⁃regulated kinase kinase⁃1 and mitogen⁃activated protein kinase/extracellular signal⁃regulated kinase kinase kinase⁃1: in vivo effects on cutaneous inflammatory responses by topical administration［J］. J Pharmacol Exp Ther, 2010, 335（1）: 23⁃31. DOI: 10.1124/jpet.110.168583.
［17］	Crawshaw AA, Griffiths CE, Young HS. Investigational VEGF antagonists for psoriasis［J］. Expert Opin Investig Drugs, 2012, 21（1）: 33⁃43. DOI: 10.1517/13543784.2012.636351.
［18］	Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor ［J］. Am J Pathol, 2008, 173（1）: 265⁃277. DOI: 10.2353/ajpath.2008.071074.
［19］	Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: Results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis［J］. Acta Derm Venereol, 2015, 95（5）: 542⁃548. DOI: 10.2340/00015555⁃2047.
［20］	Xiao S, Yosef N, Yang J, et al. Small⁃molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms［J］. Immunity, 2014, 40（4）: 477⁃489. DOI: 10.1016/j.immuni.2014.04.004.